Jasper Therapeutics, Inc. (JSPR) · Oct 15, 2026 · Other events

Jasper Therapeutics completes IgAN enrollment, accelerates FSGS

IgAN enrollment complete — 18 patients enrolled; interim data expected by year-end 2026

Jasper Therapeutics completes IgAN enrollment for KP104 and accelerates its FSGS cohort, but the real test remains year-end interim data.

Jasper is rebuilding around Kira’s complement pipeline, with KP-104 now its lead renal-development asset. Following the July 2026 merger, management identified KP-104 as a Phase 2/3-ready program in PNH and high-unmet-need nephrology, with Stage 1 renal data already expected in the fourth quarter of 2026; the August financing was intended to fund planned operations through the second half of 2028. This filing advances that story operationally, not clinically. Jasper completed enrollment of the first IgAN cohort, with 18 patients spread across three maintenance-dosing schedules. The milestone puts the company in position to generate its first renal proof-of-concept signal, but it provides no new efficacy or safety readout. The incremental surprise is the expansion pace. Jasper says enrollment was completed on schedule and that initiation of the FSGS cohort has been accelerated, with first dosing anticipated in the first quarter of 2027. 〔0〕 Because the prior corporate update already pointed to interim renal data in the fourth quarter, this is partly a confirmation rather than a wholesale change in expectations. The key catalyst is now clearly defined. The company expects initial interim IgAN data by year-end 2026. 〔1〕 That result—not enrollment completion—will determine whether KP-104’s dual-complement rationale translates into a meaningful clinical signal. Bottom line: This modestly strengthens Jasper’s execution story and broadens the renal program, but the business remains dependent on the pending IgAN data rather than today’s enrollment milestone.

What to watch next

IgAN interim data by year-end 2026

Original filing on SEC EDGAR

More Jasper Therapeutics, Inc. news

Jasper Therapeutics completes IgAN enrollment, accelerates FSGS | JSPR Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.